Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in HFpEF and Pulmonary Vascular Disease
NCT03153111Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) comparing Macitentan with Placebo (2 arms). Primary endpoint: N-terminal Pro-brain Natriuretic Peptide at 24 weeks. Started Jul 2017; status: completed.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on NCT03153111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153111.